Cargando…
Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
SIMPLE SUMMARY: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid neoplasms characterized, at the time of their presentation, by the simultaneous presence of both myelodysplastic and myeloproliferative features. In MDS/MPN, the karyotype is often normal but mutations in genes...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124412/ https://www.ncbi.nlm.nih.gov/pubmed/33925681 http://dx.doi.org/10.3390/cancers13092120 |
_version_ | 1783693198133035008 |
---|---|
author | Palomo, Laura Acha, Pamela Solé, Francesc |
author_facet | Palomo, Laura Acha, Pamela Solé, Francesc |
author_sort | Palomo, Laura |
collection | PubMed |
description | SIMPLE SUMMARY: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid neoplasms characterized, at the time of their presentation, by the simultaneous presence of both myelodysplastic and myeloproliferative features. In MDS/MPN, the karyotype is often normal but mutations in genes that are common across myeloid neoplasms can be detected in a high proportion of cases by targeted sequencing. In this review, we intend to summarize the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of patients. ABSTRACT: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are myeloid neoplasms characterized by the presentation of overlapping features from both myelodysplastic syndromes and myeloproliferative neoplasms. Although the classification of MDS/MPN relies largely on clinical features and peripheral blood and bone marrow morphology, studies have demonstrated that a large proportion of patients (~90%) with this disease harbor somatic mutations in a group of genes that are common across myeloid neoplasms. These mutations play a role in the clinical heterogeneity of these diseases and their clinical evolution. Nevertheless, none of them is specific to MDS/MPN and current diagnostic criteria do not include molecular data. Even when such alterations can be helpful for differential diagnosis, they should not be used alone as proof of neoplasia because some of these mutations may also occur in healthy older people. Here, we intend to review the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of the patients. |
format | Online Article Text |
id | pubmed-8124412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81244122021-05-17 Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms Palomo, Laura Acha, Pamela Solé, Francesc Cancers (Basel) Review SIMPLE SUMMARY: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid neoplasms characterized, at the time of their presentation, by the simultaneous presence of both myelodysplastic and myeloproliferative features. In MDS/MPN, the karyotype is often normal but mutations in genes that are common across myeloid neoplasms can be detected in a high proportion of cases by targeted sequencing. In this review, we intend to summarize the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of patients. ABSTRACT: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are myeloid neoplasms characterized by the presentation of overlapping features from both myelodysplastic syndromes and myeloproliferative neoplasms. Although the classification of MDS/MPN relies largely on clinical features and peripheral blood and bone marrow morphology, studies have demonstrated that a large proportion of patients (~90%) with this disease harbor somatic mutations in a group of genes that are common across myeloid neoplasms. These mutations play a role in the clinical heterogeneity of these diseases and their clinical evolution. Nevertheless, none of them is specific to MDS/MPN and current diagnostic criteria do not include molecular data. Even when such alterations can be helpful for differential diagnosis, they should not be used alone as proof of neoplasia because some of these mutations may also occur in healthy older people. Here, we intend to review the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of the patients. MDPI 2021-04-27 /pmc/articles/PMC8124412/ /pubmed/33925681 http://dx.doi.org/10.3390/cancers13092120 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Palomo, Laura Acha, Pamela Solé, Francesc Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms |
title | Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms |
title_full | Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms |
title_fullStr | Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms |
title_full_unstemmed | Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms |
title_short | Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms |
title_sort | genetic aspects of myelodysplastic/myeloproliferative neoplasms |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124412/ https://www.ncbi.nlm.nih.gov/pubmed/33925681 http://dx.doi.org/10.3390/cancers13092120 |
work_keys_str_mv | AT palomolaura geneticaspectsofmyelodysplasticmyeloproliferativeneoplasms AT achapamela geneticaspectsofmyelodysplasticmyeloproliferativeneoplasms AT solefrancesc geneticaspectsofmyelodysplasticmyeloproliferativeneoplasms |